VBI Vaccines Inc.

Name: VBI Vaccines Inc.
Address: 160 Second Street, Floor 3, Cambridge, MA, 02142, US
Telephone: +16178303031
Price range: $

Home
United States
Cambridge, MA
VBI Vaccines Inc.

VBI is developing a next generation of vaccines to address unmet needs in infectious disease and imm VBI Vaccines Inc.

(Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only commercially-approved trivalent hepatitis B vaccine, Sci-B-Vac®, which is approved for use in Israel and 10 other countries and recently completed its Pha

se 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. Integrating its cytomegalovirus (CMV) expertise with the eVLP platform technology, VBI’s lead eVLP program candidates include a prophylactic CMV vaccine candidate and a glioblastoma (GBM) vaccine immunotherapeutic candidate. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

02/29/2024

Though a rare disease, accounts for nearly half of all malignant brain tumors with an estimated 12,000 people diagnosed annually in the U.S. Today and every day we strive to provide new treatment options for patients with .
National Organization for Rare Disorders, Inc. (NORD)

03/03/2023

ICYMI: Jeff Baxter, CEO, and David E Anderson, CSO, recently sat down with analyst Steven Seedhouse, Ph.D., of Raymond James and Associates to discuss encouraging initial Phase 2 data from our hepatitis B immunotherapeutic candidate, VBI-2601. Access the full replay here: https://bit.ly/3KPelgR

02/28/2023

Tune in today at 1pm ET to listen as Jeffrey Baxter, VBI’s President & CEO, and David E. Anderson, VBI’s Chief Scientific Officer, discuss our hepatitis B portfolio with covering analyst, Steven Seedhouse, Ph.D., of Raymond James & Associates, Inc. Access the webcast link here: https://bit.ly/3mf8uqY

12/08/2022

We are happy to share that our vaccine, PreHevbrio™ [3-Antigen Hepatitis B Vaccine (Recombinant)] is now approved by Health Canada, marking the fourth regulatory approval for this vaccine in the past year. Learn more: https://bit.ly/3UGxrae

11/22/2022

Today we shared updated tumor response, clinical response, and biomarker data from our Phase 1/2a study of VBI-1901, our immunotherapeutic candidate in recurrent glioblastoma ( ), from our poster at the SNO Annual Meeting. Click here to read the release and to access the poster: https://bit.ly/3GDbDsM

10/12/2022

Today we announced a new collaboration with Agenus in the primary setting as part of the INSIGhT adaptive platform study. We anticipate initiating enrollment in this Phase 2 study arm around year-end 2022 and look forward to sharing data from this combination therapy. Read more: https://bwnews.pr/3EEAnQe

08/22/2022

: PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] has been recognized as a 2022 USA “Best Biotechnology Product” nominee. is honored to be considered among this year’s nominees. To learn more about the Prix Galien awards, read here: https://prn.to/3dR9GN7

08/08/2022

This morning, we shared second quarter 2022 financial results and highlighted recent developments in addition to upcoming milestones. Read the full update here: https://bit.ly/3ddh8Sa

07/20/2022

GBM median overall survival rates remain too low – FDA recently granted Orphan Drug Designation to our vaccine candidate, VBI-1901, and we are working hard to provide a new treatment option for patients with this devastating disease.

07/20/2022

Today is . We are proud to partner with the National Brain Tumor Society to increase education and awareness for glioblastoma patients and their caregivers. Help us shine a light on this complex, aggressive, and underserved brain tumor.

06/22/2022

We announced today that the FDA has granted us Orphan Drug Designation for our cancer vaccine immunotherapeutic candidate, VBI-1901, for the treatment of glioblastoma. Read the full announcement here: https://bit.ly/3yaNyoi

06/07/2022

Jeff Baxter, CEO, will participate in an analyst-led fireside chat at 1:30pm ET on Wednesday, June 8 at the Jefferies Healthcare Conference. The chat will be moderated by Jefferies covering analyst Roger Song, M.D. Access the webcast link here: https://bit.ly/3mnKA9m

Address

160 Second Street, Floor 3
Cambridge, MA
02142

Telephone

+16178303031

Website

https://www.vbivaccines.com/subscribe/

Alerts

Be the first to know and let us send you an email when VBI Vaccines Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to VBI Vaccines Inc.:

Shortcuts

Want your business to be the top-listed Engineering Company in Cambridge?

VBI Vaccines Inc.

02/29/2024

03/03/2023

02/28/2023

12/08/2022

11/22/2022

10/12/2022

08/22/2022

08/08/2022

07/20/2022

07/20/2022

06/22/2022

06/07/2022

Address

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Category